The Global Viral Vector Manufacturing Market Report is Recently Published By Market Research Future Firm. Report include market exclusive analysis based on industry size, Upcoming Trends and demand supply. Viral Vector Manufacturing Market Analysis is available on MarketResearchFuture.com uniquely by 90 pages information, 30+ tables and 30+ figures exclusively.
Global Viral Vector Manufacturing Market, 2018-2023. It is estimated that the global viral vector manufacturing market is expected to grow at a CAGR ~ 22.65% with an expected market value of USD 319 million during the forecast period from 2018 to 2023.
Gene therapy is one of the preferred treatment options for most chronic diseases which involves the insertion of a functional copy of a gene into a defective cell. Viral vector methods are used in effective transfer of therapeutic gene into the target cells. Viral vectors used in gene therapy include retroviral vectors, adenoviral vectors and adeno-associated viral vectors. Rise in the number of clinical trials, increase in the number of gene therapy candidates, and the growing necessity for an effective mode of disease treatment are likely to drive the growth of the market. Also, the characteristics of viral vectors such as ability to express therapeutic genes efficiently, and non-pathogenic nature fuels the growth of the market.
Request Sample Copy at https://www.marketresearchfuture.com/sample_request/6890
Moreover, the support of the government to the companies involved in the development of viral agent-based products in readily increasing. For instance, in March 2016, National Health Service (NHS), a publicly funded national healthcare system for England announced a new process, Health Research Authority (HRA) Approval, for applying for approvals of all project-based research. Thus, this will streamline the approval process for the companies and other research institutes. However high cost of gene therapies and possible mutagenesis may restraint the growth of the market during the forecast period.
Some of the key players in the global viral vector manuacturing market are FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Kaneka Eurogentec S.A., Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics and REGENXBIO Inc.
Currently, the Global Viral Vector Manufacturing Market is dominated by several players. The prominent players in this market are involved in new product launches, strategic partnerships to expand their product portfolio. For instance, in February 2016, Cobra Biologics and the Centre for Process Innovation (CPI) announced a collaboration in which the companies will be focusing on the development of a platform for industrial manufacturing of Adeno-Associated Virus (AAV) production to support gene therapy and regenerative medicine.
On the regional basis, the Viral Vector Manufacturing Market in the Americas is anticipated to dominate the market during the forecast period. The market growth in this region is due to the well-developed healthcare sector and rising prevalence of autoimmune and chronic diseases. According to a study published by Partnership to Fight Chronic Disease (PFCD) in 2016, 191 million people in America had at least 1 chronic disease, whereas 75 million had 2 or more chronic diseases in the year 2015.
The global viral vector manufacturing market has been segmented into type, disease, and end-user.
The Americas is projected to dominate the global viral vector manufacturing market due to a well-developed healthcare sector and rising prevalence of autoimmune and chronic diseases. According to a study published by Partnership to Fight Chronic Disease (PFCD) in 2016, 191 million people in America had at least 1 chronic disease, whereas 75 million had 2 or more chronic diseases in the year 2015. Europe is expected to hold the second largest position in the global viral vector manufacturing market. The market growth in this region is attributed to the availability of funds for research and increasing healthcare expenditure.
Browse Complete 90 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/viral-vector-manufacturing-market-6890
According to the European Commission, in 2016 the total expenditure of the governments of the European Union on health amounted to 7.1% of GDP. Also, according to National Institute of Health Funding (NIHR) in the year 2016, a funding of Euro 928 million was announced for new NIHR Biomedical Research Centres (BRC) and NIHR Clinical Research Facilities (CRF) for 5 years starting from April 2017.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies. On the other hand, the Middle East and Africa has the least share of the market.
Brief TOC of Viral Vector Manufacturing Market Research Report – Global Forecast till 2023:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
Check Discount at https://www.marketresearchfuture.com/check-discount/6890
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312